RECIST 1.1 Tumor Response
RECIST 1.1 (Eisenhauer et al., 2009)Assigns the RECIST 1.1 overall response category (CR, PR, SD or PD) for a single follow-up time point from the change in the sum of target-lesion diameters, the non-target lesion status and the presence of new lesions.
Also searched as: oncology · target lesion · clinical trials · CT · MRI · chemotherapy
Information
Incomplete input
- Please provide: baseline sum of diameters, current sum of diameters, non-target lesion status.
How this tool works
RECIST 1.1 measures up to five target lesions (maximum two per organ) by longest diameter, or short axis for lymph nodes (target nodes must be at least 15 mm in short axis at baseline). Partial response requires at least a 30% fall in the sum of diameters versus baseline; progressive disease requires at least a 20% rise versus the smallest sum recorded on study plus an absolute increase of at least 5 mm, unequivocal worsening of non-target disease, or any new lesion. Complete response needs disappearance of all target lesions with every pathological node back below 10 mm short axis. This tool works on entered sums rather than per-lesion tables, so the user should compute the sum of diameters first; nodes that shrink below 10 mm short axis count as normal. When response rate is a primary trial endpoint, CR and PR must be confirmed on a repeat scan no sooner than 4 weeks later.
References
- Eisenhauer EA et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
- RECIST 1.1 response evaluation categories for target and non-target lesions (open-access summary tables)
Implemented from the cited published sources. Educational use only; confirm against current guidelines before clinical use.
Clinical questions that use this
Named by 7 vetting guides, including these.